ACA replacement set for vote in House on March 23

John Gregory | | Health Exec | Policy & Regulations

The Republican-sponsored replacement for the Affordable Care Act (ACA), the American Health Care Act (AHCA), will get a vote in the full U.S. House on March 23, despite doubts that it has enough votes to pass.

The Republican majority in the House could fail to pass the bill if more conservative members vote against it. A source familiar with positions of members of the House Freedom Caucus told The Hill that despite conservative changes to the bill, such as allowing states to impose work requirements on Medicaid beneficiaries, the group remains opposed to the legislation.

"If the bill were brought to the floor today, it would fail to get enough votes," said the unnamed source.

Republicans can afford to lose 21 votes in the House. In the Senate, it can only lose two—and Democratic leaders have already said no member of their party will support the bill after estimates that it would result in 24 million more uninsured by 2026.

Read the full article below:

Week ahead: House heads for Thursday vote on ObamaCare repeal

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Related Content

‘A huge win’: CMS significantly increases Medicare payments for cardiac CT
Kentucky AG launches criminal probe after conscious man nearly has organs harvested
FDA announces Class I recall of ventilators after 3 patient injuries
FDA clears AI tool that flags signs of heart disease in chest CT scans
Stewardship Health sale to private equity finalized for $245M
Baxter producing IV solutions ahead of schedule at Asheville-area site

Around the web

Cardiovascular Business
Q&A: Why are cardiovascular devices involved in so many recalls? FDA policies may be to blame

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Cardiovascular Business
Cardiologist compensation still rising, especially in invasive and interventional cardiology

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Cardiovascular Business
FDA’s tirzepatide decision creates uncertainty for patients—and leads to a lawsuit

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Design by Adaptive Theme
Trimed Popup
Trimed Popup